颖泰生物连亏2年 西南证券保荐上市2021年转板北交所

Core Viewpoint - YingTai Bio (920819.BJ) reported a projected revenue of 5.531 billion yuan for 2025, a decrease of 2.27% compared to the previous year, while the net profit attributable to shareholders is expected to be -250 million yuan, an increase of 57.45% year-on-year [1][3]. Financial Performance Summary - Revenue: The company expects to achieve a revenue of 5.531 billion yuan, down 2.27% from 5.659 billion yuan in the same period last year [1][3]. - Net Profit: The net profit attributable to shareholders is projected at -250 million yuan, which is an improvement of 57.45% from -587 million yuan in the previous year [1][3]. - Net Profit Excluding Non-Recurring Items: The net profit excluding non-recurring items is expected to be -274 million yuan, up 53.91% from -595 million yuan year-on-year [1][3]. Previous Year Comparison - 2024 Revenue: The revenue for 2024 was reported at 5.659 billion yuan, a slight decline of 0.62% from 5.695 billion yuan in 2023 [5]. - 2024 Net Profit: The net profit attributable to shareholders for 2024 was -587 million yuan, a significant decrease of 713.83% compared to a profit of 95.7 million yuan in 2023 [5]. - 2024 Net Profit Excluding Non-Recurring Items: The net profit excluding non-recurring items for 2024 was -595 million yuan, down 1309.89% from a profit of 49.2 million yuan in 2023 [5]. Company Background - YingTai Bio was listed on the New Third Board's selected layer on July 27, 2020, and transitioned to the Beijing Stock Exchange on November 15, 2021 [5]. - The company issued 10 million shares, accounting for 8.16% of the total share capital post-issue, with a total capital raised of 545 million yuan [6].